Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 2, 2026

Ex-Southern California Real Estate Agent Selling $900K Condo Asks Why People Are Still Paying 5% Commission — 'Shelling Out 45K' For MLS Listing 'Seems Crazy'

View original at finance.yahoo.com
Ex-Southern California Real Estate Agent Selling $900K Condo Asks Why People Are Still Paying 5% Commission — 'Shelling Out 45K' For MLS Listing 'Seems Crazy' Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Elf Labs' valuation growth exceeded 1,600% in under two years

    80% confidence
  • Former real estate agent questions why sellers still pay 5% commission ($45,000 on $900,000 condo) for loading information on MLS and maybe holding open house

    80% confidence
  • Rad AI's artificial intelligence technology helps transform data chaos into actionable insights for high-performing content with measurable ROI

    80% confidence
  • In New York, attorneys handle much of the real estate paperwork

    80% confidence
  • Paladin Power's ESS uses non-lithium, solid-state graphene battery technology as alternative to fire-prone storage solutions

    80% confidence
  • Arrived Homes' Private Credit Fund has historically paid an annualized dividend yield of 8.1%

    80% confidence
  • Commissions were always negotiable in theory, but recent changes made negotiation more explicit in practice

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com